Show simple item record

dc.contributor.authorClissold, RL
dc.contributor.authorShaw-Smith, C
dc.contributor.authorTurnpenny, P
dc.contributor.authorBunce, B
dc.contributor.authorBockenhauer, D
dc.contributor.authorKerecuk, L
dc.contributor.authorWaller, S
dc.contributor.authorBowman, P
dc.contributor.authorFord, T
dc.contributor.authorEllard, S
dc.contributor.authorHattersley, AT
dc.contributor.authorBingham, C
dc.date.accessioned2016-10-13T11:30:16Z
dc.date.issued2016-05-24
dc.description.abstractHeterozygous mutations of the HNF1B gene are the commonest known monogenic cause of developmental kidney disease. Half of patients have a deletion (approximately 1.3 Mb) of chromosome 17q12, encompassing HNF1B plus 14 additional genes. This 17q12 deletion has been linked with an increased risk of neurodevelopmental disorders, such as autism. Here we compared the neurodevelopmental phenotype of 38 patients with HNF1B-associated renal disease due to an intragenic mutation in 18 patients or due to 17q12 deletion in 20 patients to determine whether haploinsufficiency of HNF1B is responsible for the neurodevelopmental phenotype. Significantly, brief behavioral screening in children with the deletion showed high levels of psychopathology and its impact. Eight individuals (40%) with a deletion had a clinical diagnosis of a neurodevelopmental disorder compared to none with an intragenic mutation. The 17q12 deletions were also associated with more autistic traits. Two independent clinical geneticists were able to predict the presence of a deletion with a sensitivity of 83% and specificity of 79% when assessing facial dysmorphic features as a whole. Thus, the 17q12 deletions but not HNF1B intragenic mutations are associated with neurodevelopmental disorders. Hence, the HNF1B gene is not involved in the neurodevelopmental phenotype of these patients. Nephrologists need to be aware of this association to ensure appropriate referral to psychiatric services.en_GB
dc.description.sponsorshipRC is supported by a Medical Research Council Clinical Training Fellowship (grant reference number MR/J011630/1). AH is a core member of the National Institute for Health Research Exeter Clinical Research Facility and a National Institute for Health Research Senior Investigator. SE and AH are supported by a Wellcome Trust Senior Investigator award.en_GB
dc.identifier.citationVol. 90, Iss. 1, July 2016, pp. 203 - 211en_GB
dc.identifier.doi10.1016/j.kint.2016.03.027
dc.identifier.otherS0085-2538(16)30115-6
dc.identifier.urihttp://hdl.handle.net/10871/23895
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/27234567en_GB
dc.rightsThis is the author accepted manuscript. This is an open access article. The final version is available from Elsevier via the DOI in this record.en_GB
dc.subject17q12 deletionen_GB
dc.subjectHNF1Ben_GB
dc.subjectcystic kidneysen_GB
dc.subjectdevelopmental kidney diseaseen_GB
dc.subjectneurodevelopmental disordersen_GB
dc.titleChromosome 17q12 microdeletions but not intragenic HNF1B mutations link developmental kidney disease and psychiatric disorder.en_GB
dc.typeArticleen_GB
dc.date.available2016-10-13T11:30:16Z
dc.identifier.issn0085-2538
exeter.place-of-publicationUnited Statesen_GB
dc.descriptionPublisheden_GB
dc.descriptionJournal Articleen_GB
dc.identifier.eissn1523-1755
dc.identifier.journalKidney Internationalen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record